About NextPoint Therapeutics
NextPoint Therapeutics is a private company based in Cambridge, Massachusetts. It has reported $156,208,152 raised in three offerings on Form D since December 2022. Its chief executive is Ivan Cheung.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 22, 2026 | Jul 30, 2026 | $33,728,772of $48.7M target | 15 | $2.2M | Equity, OptionsRule 506(b) | Form D ↗ |
| Jan 31, 2024 | Feb 14, 2024 | $42,479,388fully sold | 15 | $2.8M | EquityRule 506(b) | Form D ↗ |
| Dec 13, 2022 | Dec 27, 2022 | $79,999,992fully sold | 13 | $6.1M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $156,208,152 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on NextPoint Therapeutics's Form D filed Jul 30, 2026.
R. Jacob Vogelstein
Board Member
JL
Earlier filings also listed Paul Conrad (secretary and treasurer, last listed Feb 2024), Matthew Roden (director, last listed Feb 2024) and Ansbert Gadicke (director, last listed Dec 2022).